Cargando…

A structure-function approach to optimizing TLR4 ligands for human vaccines

Adjuvants are combined with vaccine antigens to enhance and modify immune responses, and have historically been primarily crude, undefined entities. Introducing toll-like receptor (TLR) ligands has led to a new generation of adjuvants, with TLR4 ligands being the most extensively used in human vacci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carter, Darrick, Fox, Christopher B, Day, Tracey A, Guderian, Jeffrey A, Liang, Hong, Rolf, Tom, Vergara, Julie, Sagawa, Zachary K, Ireton, Greg, Orr, Mark T, Desbien, Anthony, Duthie, Malcolm S, Coler, Rhea N, Reed, Steven G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133366/ https://www.ncbi.nlm.nih.gov/pubmed/27990284 http://dx.doi.org/10.1038/cti.2016.63

Ejemplares similares

A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7
por: Fox, Christopher B, et al.
Publicado: (2014)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
por: Coler, Rhea N., et al.
Publicado: (2011)

Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity
por: Fung, HW Millie, et al.
Publicado: (2013)

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE
por: Coler, Rhea N, et al.
Publicado: (2015)

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
por: Coler, Rhea N., et al.
Publicado: (2018)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis
por: Duthie, Malcolm S., et al.
Publicado: (2016)

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model
por: Baldwin, Susan L., et al.
Publicado: (2021)

Formulated Phospholipids as Non-Canonical TLR4 Agonists
por: Liang, Hong, et al.
Publicado: (2022)

Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites
por: Hofmeyer, Kimberly A., et al.
Publicado: (2016)

Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice
por: Paes, Wayne, et al.
Publicado: (2016)

Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development
por: Sampaio, Lucas H, et al.
Publicado: (2011)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

A defined subunit vaccine that protects against vector-borne visceral leishmaniasis
por: Duthie, Malcolm S., et al.
Publicado: (2017)

Adjuvants for Leishmania vaccines: from models to clinical application
por: Raman, Vanitha S., et al.
Publicado: (2012)

High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis
por: de Oliveira, Fabrícia Alvisi, et al.
Publicado: (2013)

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen
por: Van Hoeven, Neal, et al.
Publicado: (2018)

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations
por: Van Hoeven, Neal, et al.
Publicado: (2016)

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
por: Baldwin, Susan L., et al.
Publicado: (2018)

TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes
por: McKay, Paul F., et al.
Publicado: (2016)

pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG
por: Wu, Jing, et al.
Publicado: (2019)

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
por: Coler, Rhea N., et al.
Publicado: (2010)

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach
por: Fox, Christopher B., et al.
Publicado: (2016)

Skin tests for the detection of Mycobacterial infections: achievements, current perspectives, and implications for other diseases
por: Duthie, Malcolm S., et al.
Publicado: (2021)

The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6
por: Irvine, Katherine Lucy, et al.
Publicado: (2013)

Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasis
por: Ghosh, Prakash, et al.
Publicado: (2016)

Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions
por: Fisher, Karl J., et al.
Publicado: (2023)

Transcriptome sequencing of microglial cells stimulated with TLR3 and TLR4 ligands
por: Das, Amitabh, et al.
Publicado: (2015)

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
por: Fox, Christopher B., et al.
Publicado: (2012)

The adjuvant GLA-AF enhances human intradermal vaccine responses
por: Carter, Darrick, et al.
Publicado: (2018)

Editorial: Beyond Th1: Novel concepts in tuberculosis vaccine immunology
por: Dijkman, Karin, et al.
Publicado: (2022)

Toll-Like Receptor Ligand-Induced Liver Injury in D-Galactosamine-Sensitized Mice: Differences between TLR7/8 and TLR9 Ligands, Cytokine Patterns, and Cross-Tolerance Induction by TLR2 Ligand Pretreatment
por: Seki, Reiko
Publicado: (2017)

BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer
por: Śmiałek-Bartyzel, Justyna, et al.
Publicado: (2023)

Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants
por: Olafsdottir, Thorunn A., et al.
Publicado: (2016)

Contrasting Roles for TLR Ligands in HIV-1 Pathogenesis
por: Brichacek, Beda, et al.
Publicado: (2010)

TLR Ligands Induce Antiviral Responses in Chicken Macrophages
por: Barjesteh, Neda, et al.
Publicado: (2014)

Local Innate Responses to TLR Ligands in the Chicken Trachea
por: Barjesteh, Neda, et al.
Publicado: (2016)

Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
por: Larsen, Sasha E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qio3gsqctsotcuj4q1tdthig8l